Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B for neuro start-up CoLucid raises $25mm

Executive Summary

First-time backer Care Capital has led the $25mm Series B financing for CoLucid Pharmaceuticals (lead candidate for migraine plus preclinical programs for several other neurological diseases) and contributed a new board member to the company. Returning shareholders Pappas Ventures, Domain Associates, Pearl Street Venture Funds, and Triathlon Medical Ventures also participated. CoLucid will use to money to move its 5HT1F agonist COL144 into Phase III and test the compound's anti-migraine efficacy as an oral medicine.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies